

This article was originally published [here](#)

Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Asset Management, BVF Partners, and investor HBM

The post [ALX Oncology announces closing of \\$105m Series C financing](#) appeared first on [Pharmaceutical Business review](#).